Erratum: Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro (BMC Cancer (2013) 13 (21) DOI: 10.1186/1471-2407-13-21);Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Rong, Minhua ^a   Chen, Gang ^a   Dang, Yiwu ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase; Cell cycle; Cell growth; Hepatocellular carcinoma (HCC); MiR 221

Indexed keywords

CASPASE 3; CASPASE 7; MICRORNA 221;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL STRAIN HEPG2; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; FLUOROMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY;

EID: 84872182721     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-020-6680-3     Document Type: Erratum

References (62)

1. Kudo M. Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology 2011, 81(Suppl 1):1-10.
2. Meguro M, Mizuguchi T, Kawamoto M, Hirata K. The molecular pathogenesis and clinical implications of hepatocellular carcinoma. Int J Hepatol 2011, 2011:818672. 3235480, 22187659.
3. Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. Dig Dis 2011, 29:284-288. 10.1159/000327560, 21829019.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156. 10.1002/ijc.1440, 11668491.
5. Zemel R, Issachar A, Tur-Kaspa R. The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011, 15:261-279. vii-x, 10.1016/j.cld.2011.03.001, 21689612.
6. Vertemati M, Moscheni C, Petrella D, Lamperti L, Cossa M, Gambacorta M, Goffredi M, Vizzotto L. Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis. Pathol Res Pract 2012, 208:240-244. 10.1016/j.prp.2012.02.007, 22429827.
7. Hu Z, Zhao W. Novel insights into the molecular mechanisms of alpha-fetoprotein expression and malignant phenotypes of hepatocellular carcinoma. Cell Mol Immunol 2012, 9:7-8. 10.1038/cmi.2011.30, 21860406.
8. Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses 2009, 1:852-872. 10.3390/v1030852, 3185529, 21994573.
9. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48:2047-2063. 10.1002/hep.22580, 19003900.
10. Katzenellenbogen M, Mizrahi L, Pappo O, Klopstock N, Olam D, Barash H, Domany E, Galun E, Goldenberg D. Molecular mechanisms of the chemopreventive effect on hepatocellular carcinoma development in Mdr2 knockout mice. Mol Cancer Ther 2007, 6:1283-1291. 10.1158/1535-7163.MCT-06-0420, 17431106.
11. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 2008, 14:470-477. 10.1158/1078-0432.CCR-07-0586, 18223221.
12. Hu L, Chen G, Yu H, Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int 2010, 4:423-432. 10.1007/s12072-010-9164-8, 2836437, 20305761.
13. Chen G, Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 2008, 21:275-278.
14. Chen G, Dang YW, Luo DZ, Feng ZB, Tang XL. Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res 2008, 17:183-189. 10.3727/096504008785114138, 18773863.
15. Giorgio A. Percutaneous radiofrequency ablation of hepatocellular carcinoma on cirrhosis: state of the art and future perspectives. Recent Pat Anticancer Drug Discov 2010, 5:69-76.
16. Lencioni R, Cioni D, Crocetti L, Bartolozzi C. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl 2004, 10:S91-97. 10.1002/lt.20043, 14762847.
17. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011, 37:212-220. 10.1016/j.ctrv.2010.07.006, 20724077.
18. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23:6657-6663. 10.1200/JCO.2005.14.696, 16170173.
19. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27:843-850. 10.1200/JCO.2008.18.3301, 19139433.
20. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898-1903. 10.1200/JCO.2005.04.9130, 16622265.
21. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009, 10:794-800. 10.1016/S1470-2045(09)70171-8, 19586800.
22. Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:2498. author reply 2498-2499.
23. Copur MS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:2498. author reply 2498-2499.
24. Spinzi G, Paggi S. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:2497-2498. author reply 2498-2499.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
26. Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol 2011, 676:3-22. 10.1007/978-1-60761-863-8_1, 20931386.
27. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011, 10:38. 10.1186/1476-4598-10-38, 3098824, 21489289.
28. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010, 46:298-311. 10.1016/j.ejca.2009.10.027, 19948396.
29. Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int 2012, 32:772-782. 10.1111/j.1478-3231.2012.02795.x, 22429613.
30. Negrini M, Gramantieri L, Sabbioni S, Croce CM. microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 2011, 11:500-521. 10.2174/187152011796011037, 21554203.
31. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011, 6:e16435. 10.1371/journal.pone.0016435, 3029327, 21298008.
32. Diao S, Zhang JF, Wang H, He ML, Lin MC, Chen Y, Kung HF. Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma. Proteomics 2010, 10:3723-3731. 10.1002/pmic.201000050, 20859956.
33. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 2010, 6:402. 2950084, 20739924.
34. Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q, et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009, 39:786-794. 10.1111/j.1872-034X.2009.00502.x, 19473441.
35. Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112. 10.1002/hep.22749, 19173277.
36. Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, Sun Z, Wei L, Zheng X. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. Hepatology 2009, 49:1194-1202. 10.1002/hep.22757, 19133651.
37. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008, 12:2189-2204. 10.1111/j.1582-4934.2008.00533.x, 19120703.
38. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008, 283:13205-13215. 10.1074/jbc.M707629200, 18319255.
39. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, Odenthal M. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 2008, 47:1223-1232.
40. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, Calin GA, Giovannini C, Ferrazzi E, Grazi GL, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007, 67:6092-6099. 10.1158/0008-5472.CAN-06-4607, 17616664.
41. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545. 10.1038/sj.onc.1209283, 16331254.
42. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2011,
43. Fu X, Wang Q, Chen J, Huang X, Chen X, Cao L, Tan H, Li W, Zhang L, Bi J, et al. Clinical significance of miR-221 and its inverse correlation with p27Kip(1) in hepatocellular carcinoma. Mol Biol Rep 2011, 38:3029-3035. 10.1007/s11033-010-9969-5, 20146005.
44. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010, 107:264-269. 10.1073/pnas.0907904107, 2806773, 20018759.
45. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009, 15:5073-5081. 10.1158/1078-0432.CCR-09-0092, 19671867.
46. Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008, 135:257-269. 10.1053/j.gastro.2008.04.003, 18555017.
47. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008, 27:5651-5661. 10.1038/onc.2008.178, 18521080.
48. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509. 10.1016/j.ccr.2009.10.014, 2796583, 19962668.
49. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006. 10.1038/cr.2008.282, 18766170.
50. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010, 9:306. 10.1186/1476-4598-9-306, 3002336, 21110877.
51. Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011, 406:70-73. 10.1016/j.bbrc.2011.01.111, 21295551.
52. Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, et al. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 2013, 57:299-310. 10.1002/hep.25984, 22821679.
53. Dai R, Li J, Liu Y, Yan D, Chen S, Duan C, Liu X, He T, Li H. miR-221/222 suppression protects against endoplasmic reticulum stress-induced apoptosis via p27(Kip1)- and MEK/ERK-mediated cell cycle regulation. Biol Chem 2010, 391:791-801.
54. Sharma AD, Narain N, Handel EM, Iken M, Singhal N, Cathomen T, Manns MP, Scholer HR, Ott M, Cantz T. MicroRNA-221 regulates FAS-induced fulminant liver failure. Hepatology 2011, 53:1651-1661. 10.1002/hep.24243, 21400558.
55. Lu Q, Lu C, Zhou GP, Zhang W, Xiao H, Wang XR. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol Oncol 2010, 28:635-641. 10.1016/j.urolonc.2009.06.005, 19767219.
56. Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T, Schmittgen TD. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011, 71:7608-7616. 10.1158/0008-5472.CAN-11-1144, 22009537.
57. Sobin LH, Compton CC. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 2010, 116:5336-5339. 10.1002/cncr.25537, 20665503.
58. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711. 10.1093/jnci/djn134, 18477802.
59. Chen G, Kronenberger P, Umelo IA, Teugels E, De Grève J. Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem 2010, 398:266-268. 10.1016/j.ab.2009.11.034, 19961825.
60. Chen G, Kronenberger P, Teugels E, De Grève J. Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online 2011, 13:1.
61. Chen G, Kronenberger P, Teugels E, Adaku Umelo I, De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med 2012, 10:28. 10.1186/1741-7015-10-28, 3334713, 22436374.
62. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.